Hybridoma and anti-KC-4 humanized monoclonal antibody
AssigneeCoulter Corporation
InventorsF. J. R. do Couto, R. L. Ceriani, J. A. Peterson
Life of this patent
Estimating the term…
Loading patent…
AssigneeCoulter Corporation
InventorsF. J. R. do Couto, R. L. Ceriani, J. A. Peterson
Estimating the term…
An anti-KC-4 humanized monoclonal antibody that comprises the variable regions of the light and heavy chains of the anti-KC-4 murine antibody, wherein the light chain has 7 amino acids and the heavy chain has 12 amino acids of the framework regions substituted with amino acid present in equivalent positions in antibodies of a species other than munne, and the constant regions of a human antibody. The antibody may be labeled and/or glycosylated, and is presented as a composition with a carrier. The anti-KC-4 monoclonal antibody is used in diagnostic kits for cancer and in in vivo methods of imaging and treating a primary or metastasized cancer, and in vitro diagnosis and ex vivo purging neoplastic cells from a biological fluid. RNAs and DNAs encode the monoclonal antibody, and a hybrid vector carrying the nucleotides and transfected cells express the peptides.
A modified chimeric antibody which selectively binds to the human KC-4 antigen, comprising (1) the variable regions of the light and heavy chains of an anti-KC-4 murine antibody and (2) light and heavy chain constant regions of a human antibody, wherein the amino acid sequence of the variable regions comprises SEQ ID NOS:
Dependencies are inferred from the claim text.